The Relationship of Mucus Concentration (Hydration) to Mucus Osmotic Pressure and Transport in Chronic Bronchitis by Anderson, Wayne H. et al.
&get_box_var;ORIGINAL ARTICLE
The Relationship of Mucus Concentration (Hydration) to Mucus
Osmotic Pressure and Transport in Chronic Bronchitis
Wayne H. Anderson1*, Raymond D. Coakley1*, Brian Button2*, Ashley G. Henderson1*, Kirby L. Zeman3, Neil E. Alexis3,
David B. Peden3, Eduardo R. Lazarowski2, C. William Davis2, Summer Bailey2, Fred Fuller1, Martha Almond1,
Bahjat Qaqish4, Elena Bordonali4, Michael Rubinstein5, William D. Bennett1,3, Mehmet Kesimer 2, and
Richard C. Boucher1,2
1Pulmonary and Critical Care Medicine, Department of Medicine, 2Marsico Lung Institute/Cystic Fibrosis Research Center, 3Marsico
Lung Institute/Center for Environmental Medicine, Asthma, and Lung Biology, 4Department of Statistics, and 5Department of Chemistry,
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Abstract
Rationale: Chronic bronchitis (CB) is characterized by persistent
cough and sputum production. Studies were performed to test
whether mucus hyperconcentration and increased partial osmotic
pressure, in part caused by abnormal purine nucleotide regulation of
ion transport, contribute to the pathogenesis of CB.
Objectives:We tested the hypothesis that CB is characterized by
mucus hyperconcentration, increased mucus partial osmotic
pressures, and reduced mucus clearance.
Methods:Wemeasured in subjects with CB as compared with normal
and asymptomatic smoking control subjects indices of mucus
concentration (hydration; i.e., percentage solids) and sputum adenine
nucleotide/nucleosideconcentrations. Inaddition, sputumpartialosmotic
pressures and mucus transport rates were measured in subjects with CB.
Measurements and Results: CB secretions were
hyperconcentrated as indexed by an increase in percentage solids
and total mucins, in part reflecting decreased extracellular
nucleotide/nucleoside concentrations. CB mucus generated
concentration-dependent increases in partial osmotic pressures
into ranges predicted to reduce mucus transport. Mucociliary
clearance (MCC) in subjects with CBwas negatively correlated with
mucus concentration (percentage solids). As a test of relationships
between mucus concentration and disease, mucus concentrations
and MCC were compared with FEV1, and both were significantly
correlated.
Conclusions:Abnormal regulation of airway surface hydrationmay
slow MCC in CB and contribute to disease pathogenesis.
Keywords: COPD; mucociliary clearance; mucus
hyperconcentration
Chronic bronchitis (CB) is a common
respiratory disease that is often caused by
exposure to environmental toxicants,
especially tobacco smoke (1–3). CB is defined
epidemiologically by a productive chronic
cough for 3 or more consecutive months
for 2 consecutive years. CB is clinically
characterized by mucus hypersecretion,
sputum production, and it may or may not
be associated with airflow obstruction (4, 5).
If airflow obstruction occurs, CB is
categorized as part of the chronic obstructive
pulmonary disease (COPD) spectrum.
Investigations into the pathogenesis of the
mucus abnormalities in CB have included
studies of mucus viscoelastic properties,
sputum microbiology, and mucus clearance
rates (6–10).
Despite these investigations, it has been
difficult to generate a formulation that
quantitatively describes the pathogenesis of
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the mucus abnormalities in CB or identifies
objective biomarkers to complement the
reliance on symptoms for diagnosis (11–15).
Recently, a formulation has been
proposed that integrates abnormalities
of airway surface hydration and mucin
hypersecretion into parameters related to
mucus concentration to predict mucus flow
in health versus absence of flow in disease
(16, 17). In this “two-gel” model, the airway
surface is comprised of two osmotically
active polymer hydrogels, a mucus layer gel
containing secreted mucins and a “brush-
like” gel comprised of tethered mucins in the
periciliary (PCL) region. The distribution of
water between these two apposing hydrogels
is governed by the partial osmotic pressures
(“water drawing power”) generated by the
concentrations of the high-molecular-weight
polymers (typically mucins) and proteins in
each layer.
Healthy airways sense and maintain
normal mucus concentrations (hydration)
via interactions of cilia with the mucus layer
during cilial propulsion of mucus (18).
Mucus concentration-dependent cilial
strain governs the rate of ATP release onto
airway surfaces, which regulates, via P2Y2R,
the balance between liquid absorption from
versus liquid secretion onto airway surfaces.
Disease can override this regulatory
system to produce relative dehydration
of the mucus layer, (i.e., increased
mucus concentration) (19, 20). When
the concentration of the mucus layer rises
to a level that generates a partial osmotic
pressure exceeding basal PCL values, there is
osmotic compression of the PCL; slowed
mucus clearance; mucus adhesion and
accumulation; and, we postulate, the sputum
production characteristic of CB (11, 16).
In this study, we tested the hypothesis
that dehydration of the mucus lining the
conducting airways is a feature of CB and
produces decreased mucus transport. This
hypothesis was tested using cross-sectional
measurements in normal nonsmoking
subjects; smokers without symptoms or lung
disease; and subjects with CB, which included
(1) measures of mucus concentration (e.g.,
percentage solids), (2) mucus adenine
nucleotide/nucleoside concentrations, and
(3) mucus transport rates. In parallel, we
characterized the relationship between
sputum percentage solids and a key
biophysical property that governs mucus
flow (i.e., the mucus partial osmotic pressure)
(16). Some of the results of these studies have
been reported in the form of an abstract (21).
Methods
Patient Recruitment
The inclusion criteria for subjects with CB
included chronic mucus production and
cough for at least 3 months per year for
2 successive years, age 40–70, cigarette use
(>20 pack-years), and an FEV1 greater
than 35% of predicted. Subjects with
a history of atopy, a greater than 200-ml
post-bronchodilator increase in FEV1,
significant finding on electrocardiogram,
oxygen use, or a medical disorder that
placed the subject at risk, interfered with
study evaluations, or participation,
were excluded. Asymptomatic normal
nonsmoking subjects (NS) and current
cigarette smokers without symptoms
and normal lung function (CS-N) served
as control groups. The study was approved
by the University of North Carolina
institutional review board, and subjects
provided written informed consent.
Airway Mucus Sampling and Sputum
Induction
Bronchoscopic sampling of airway surface
mucus was conducted by a modification
of previously described techniques (22).
Fiberoptic bronchoscopy was performed
according to American Thoracic Society
guidelines with moderate conscious
sedation (23). No local anesthesia was
used below the cords. To measure mucus
percentage solids, preweighed, catheter-
protected filter papers were placed for 20
seconds on the surface of the bronchus
intermedius. The filter paper was
withdrawn, immediately reweighed, dried
overnight at 1008C, and reweighed after dry
weight had plateaued. Wet-to-dry ratios
were calculated as percentage solids (24).
Airway lavages (a single 50-ml aliquot of
sterile 0.9% saline) were next obtained from
the right middle lobe. Bronchoscopies were
performed 7–14 days after mucociliary
clearance (MCC) measurements. Sputum
was induced with hypertonic saline as
previously reported, following the 24-hour
MCC measurement (25).
Measurement of Sputum Percentage
Solids, Total Mucins, and Partial
Osmotic Pressure
Sputum percentage solids was measured
as previously discussed (24). The contribution
of inflammatory cells to sputum percentage
solids was determined by an experimentally
derived correction factor (see the METHODS
section in the online supplement). Total
mucin concentrations were measured by
differential refractometry combined with size
exclusion chromatography (20). CB sputum
partial osmotic pressures were measured in
triplicate using a custom-designed direct-
membrane colloid osmometer, incorporating




Sputum adenosine (ADO) and adenine
nucleotides were ethenoderivatized and
At a Glance Commentary
Scientific Knowledge on the
Subject: Chronic bronchitis (CB)
is characterized by symptoms of
cough and sputum production.
Increases in mucus concentration
(i.e., dehydration) seem to contribute
to failure of mucus clearance and are
associated with symptoms and disease
progression in CB.
What This Study Adds to the
Field: Mucus clearance is a major
mechanism protecting the lung from
inhaled infectious and noninfectious
challenges. Hydration of the mucus
layer, in part regulated by extracellular
nucleotide/nucleoside levels, is a major
determinant of the efficacy of mucus
clearance. This study characterized the
hydration status of secretions obtained
from subjects with CB and related CB
mucus concentrations (percentage
solids) to mucus partial osmotic
pressures and clearance. Increased
mucus concentrations, and decreased
extracellular nucleotide/nucleoside
levels, were a feature of CB secretions.
Increased mucus concentrations in CB
were positively correlated with mucus
partial osmotic pressure and negatively
correlated with mucus clearance rates.
Abnormal regulation of airway surface
hydration may slow clearance from the
lung in CB and contribute to an
increased risk of infection, exacerbations,
and disease pathogenesis. Testing of
therapies in subjects with CB to reduce
mucus concentration seems rational.
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measured by HPLC analysis (26).
Extracellular ATPase activity was measured
in randomly selected bronchial wash
samples (27).
Measurement of In Vitro Mucociliary
Transport Rates
Airway epithelial cells from lungs of human
organ donors were isolated as previously
described (28). Human airway epithelial
cultures (HBE) were left unwashed for 2–3
weeks to produce mucus with greater than
10% solids (16, 29). To measure MCC,
fluorescent microspheres were added
to the apical surface of HBE cultures
approximately 16 hours before study (18, 30).
MCC rates were calculated from time-lapse
fluorescent images (30). Following baseline
imaging, varying volumes of phosphate-
buffered saline were nebulized onto the HBE
surfaces to reduce mucus concentrations.
Parallel HBE cultures were used to determine
the concentration of the mucus layer after
phosphate-buffered saline aerosol exposure
using the mesh technique (16).
Measurement of Mucus Clearance
In Vivo in Subjects with CB
MCC measurements by gamma
scintigraphy were performed in subjects
with CB in the whole, central, and peripheral
lung zones using regions of interest (ROI)
analyses (31, 32). Tracheobronchial (TB)
clearance (1-TB retention) was calculated for
the first 60 minutes of radiotracer clearance
by subtraction of the 24-hour radiotracer
retention (33). The average clearance over
the 0–60 time points was computed as an
overall index of clearance rates.
Statistical Analysis
All statistical analyses were conducted using
SAS JMP Pro 9 statistical software (Cary,
NC). Correlations were determined by
Spearman correlation; F ratios less than
0.05 were considered significant. Group
comparisons used the nonparametric
Wilcoxon/Kruskal-Wallis test for
nonnormally distributed values. Tukey-
Kramer was used for all-pairs comparisons.
Covariates were evaluated using multiple
linear regression or analysis of covariance
as appropriate.
Results
Baseline demographics and pulmonary
function of the three subject groups
are presented in Table 1. The two
asymptomatic groups (NS and CS-N) were
similar in baseline lung function and age.
The subjects with CB were older, had
a greater pack-years smoking history, and
exhibited a spectrum of lung function.
Mucus and Sputum Percentage
Solids and Total Mucin
Concentrations
The mean percentage solids of mucus
samples obtained bronchoscopically
for each subject group is presented in
Figure 1A. There was an approximately
threefold increase in percentage solids in
the subjects with CB as compared with both
control groups (P, 0.0001). The smoking
control subjects were not different than
normal subjects. A similar pattern of
percentage solids was observed for induced
sputum (Figure 1B). The CB group
exhibited significantly increased sputum
percentage solids content versus the NS
group (P = 0.006) and the CS-N group (P =
0.007). Again, the smoking control group
did not differ from normal subjects.
There was also a significant increase in
sputum total mucins in the CB group versus
CS-N (P = 0.032) (Figure 1B). A significant
correlation between sputum percentage
solids and sputum total mucins was observed
in the CB group (r = 0.344; P = 0.03).
Sputum ATP and Metabolite
Concentrations
Total nucleotide concentrations in sputum
were not statistically different among the
three groups (P = 0.80). However, the
pattern of sputum concentrations of ATP
and ADO for the subject groups differed
(Figure 2A). ATP was significantly
reduced in the CS-N (P = 0.002) and CB
(P, 0.0001) groups compared with the
NS group. There were no significant
differences between groups in ADP
(adenosine diphosphate) or AMP
(adenosine monophosphate). ADO was
significant reduced in the subjects with
CB as compared with the CS-N (P = 0.03).
Because ATP and ADO are the two active
nucleotides/nucleosides regulating airway
surface liquid (ASL) volume and mucus
concentration, the sum of ATP and ADO
concentrations across groups was
compared (Figure 2B) (18, 26). The
combined ATP/ADO concentrations were
significantly lower in the CB group
(5666 73 mM) than the NS control group
(2,0036 495 mM; P = 0.0006) or the CS-
N group (1,5886 355 mM; P = 0.02).
Total Ecto-ATPase activity (percentage
ATP hydrolysis) was measured in
a randomly selected subset of bronchial
wash samples (Figure 2C). Ecto-ATPase
activity was significantly raised in the CB
group compared with the NS (P = 0.005)
and CS-N (P = 0.006) groups.
Sputum Partial Osmotic Pressure
Spontaneous sputum samples were
collected from six of the subjects with
CB over multiple periods of time and
percentage solids and partial osmotic
pressures measured (Figure 3A). The
individual data points are referenced
to a dotted line describing the







N 29 34 68
Age 26.46 6.0 30.86 8.2 58.76 10.6
Sex, % male 66 53 57
Current smokers, % 0 100 44
Pack-years 0 9.06 8.0 41.76 25.2
Race
White, % 66 68 87
Black, % 21 32 13
Hispanic, % 7 0 0
Asian, % 7 0 0
FVC, % predicted 4.856 1.05 (96.2) 4.556 1.03 (102.4) 3.386 1.01 (82.6)
FEV1, % predicted 3.916 0.8 (96.5) 3.626 0.74 (99.9) 1.966 0.87 (61.6)
FEV1/FVC 0.816 0.06 0.826 0.05 57.36 15.1
Mean6 SD.
FEV1, FVC, and FEV1/FVC are prebronchodilator for nonsymptomatic subjects and
post-bronchodilator for subjects with chronic obstructive pulmonary disease.
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relationship between percentage solids
and partial osmotic pressure of HBE
mucus harvested in vitro and
a dashed line depicting the basal
partial osmotic pressure of the PCL (16).
CB mucus samples exhibited a mucus
concentration–partial osmotic pressure
relationship similar to HBE mucus (solid
line). The partial osmotic pressure of
most spontaneously produced samples
obtained from the subjects with CB (solid
squares) exceeded that of previously
measured basal PCL values (Figure 3A)
(16). At approximately 3% solids, and
above, the partial osmotic pressure of CB
mucus is predicted to compress the PCL
and slow MCC.
Mucus Percentage Solids versus
Mucus Clearance In Vitro and In Vivo
To test the hypothesis that increased mucus
concentrations slow MCC in vitro, MCC
was measured as a function of mucus
concentration on HBE culture surfaces
in vitro. MCC rates in vitro were consistent
with in vivo rates in normal subjects in
the range of 0.5–2% solids (Figure 3B)
(34, 35). At higher percentage solids, MCC
decreased with increased concentration and
was virtually absent at percentage solids
greater than 10%.
The relationship between
bronchoscopic mucus percentage solids and
MCC was also tested in vivo in subjects with
CB (Figure 4A). The central ROI MCC data
were chosen to match the source of the
mucus samples. A negative correlation was
observed between mucus concentration,
indexed as percentage solids, and MCC
for the CB group (r =20.387; P = 0.01)
(Figure 4A). A weaker but significant
correlation was observed for induced
sputum percentage solids and MCC
(r =20.267; P = 0.033).
Adjusting for age had minimal effect
on the relationship between MCC and
the bronchoscopically obtained percentage
solids data. Adjusting for pack-years
decreased the estimated slope as expected
because of the causal role of cigarette smoke
in producing the CB phenotype. Both slopes
and intercepts for current and ex-smokers
were not different, suggesting a similar
relationship for these two groups.
Disease Status, MCC, and Mucus
Percentage Solids
Slowing of MCC, as indexed by the central
lung ROI, was associated with a reduced
FEV1 in the subjects with CB (Figure 4B)
(r = 0.338; P = 0.005). Significant
correlations between MCC and FEV1 were
also observed for the whole and peripheral
lung ROIs with FEV1% predicted (r =
0.425, P = 0.0004; and r = 0.398, P = 0.001,
respectively) (see Figures E1A and E1B
in the online supplement). Spontaneous
coughs were infrequent during the 0- to 60-
minute MCC period, averaging 0.07, 0.31,
and 1.58 coughs per 60 minutes for the
NS, CS-N, and CB groups, respectively,
indicating that cough did not influence the
measured MCC rates.
Finally, we tested the relationship

























































Figure 1. Mucus hydration and mucin
concentrations in normal subjects (NS), normal
smokers (CS-N), and subjects with chronic
bronchitis (CB). (A) Percentage solids measured
in mucus samples obtained by bronchoscopy.
The data are presented as means6 SE for each
of the three subject groups: NS (n = 24), CS-N
(n = 22), and CB (n = 43). *CB versus NS and
versus CS-N, P, 0.0001. (B) Sputum
percentage solids as means6 SE NS (n = 29),
CS-N (n = 29), and CB (n = 65); and total
sputum mucin concentration as means6 SE
NS (n = 15), CS-N (n = 15), and CB (n = 42).
*The sputum percentage solids of the CB
group were significantly higher than the NS
(P = 0.006) and the CS-N (P = 0.0007) groups.
1Similarly, the total mucin concentration was
greater in the CB group versus the CS-N group
(P = 0.032) and trended higher than the NS











































































Figure 2. Sputum nucleotide/nucleoside
concentrations. (A) Sputum adenyl nucleotide/
nucleoside concentrations (nM) are plotted as
means6 SE for the normal subjects (NS)
(n = 21), normal smokers (CS-N) (n = 21), and
chronic bronchitis (CB) (n = 45) groups.
Comparisons for all pairs (Tukey-Kramer
honestly significant difference) for ATP: *NS
versus CS-N, P = 0.002; NS versus CB,
P, 0.0001; ADP, no significant differences; AMP,
no significant differences; ADO, #CS-N versus
CB, P = 0.054. (B) Sum of ATP plus ADO
concentrations presented as means6 SE for
NS (n = 21), CS-N (n = 21), and CB (n = 45)
groups. *The ATP/ADO sum (nM) in the CB
group was significantly lower than the NS (P =
0.0006) and CS-N (P = 0.02) groups. There
were no significant differences between the
control groups. (C) Sputum Ecto-ATPase
Activity (percentage hydrolysis): data are shown
as means6 SE for the NS (n = 12), CS-N (n =
10), and CB (n = 17) groups. *Percentage
hydrolysis was significantly greater in the CB
group versus the NS (P = 0.005) and the CS-N
(P = 0.006) groups. ADO = adenosine; ADP =
adenosine diphosphate; AMP = adenosine
monophosphate.
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status. A highly significant negative
correlation was observed between FEV1%
predicted (an index of disease severity)
and percentage solids obtained
bronchoscopically (r =20.708; P, 0.0001)
in the CB group (Figure 4C). Similar
significant correlations were observed
between FEV1/FVC ratio and mucus
percentage solids (r = 0.363; P = 0.0025).
Discussion
Efficient mucus clearance is key for the
health of the lung. Genetic failures of mucus
clearance (e.g., as in cystic fibrosis and
primary ciliary dyskinesia) are associated
with cough, sputum production, and
bronchial pathology (36–39). Our study was
designed to assess the relationship between
an important property of mucus, its
concentration (“hydration”), and mucus
clearance in subjects with cigarette
smoke–induced CB over a spectrum of
disease severity.
Themost accurate assessment of airway
mucus concentration (hydration) is to
directly sample the airway surface via the
transbronchoscopic filter paper sampling
technique (24). The concentration of
normal subject’s mucus, as indexed as
percentage solids, was similar to values
reported previously for normal subjects
(20) and was not different in asymptomatic
smokers (Figure 1A). However, the
concentration of CB mucus was twofold to
threefold higher than normal. Because it
is not practical to use bronchoscopically
obtained samples for diagnosis, we also
measured induced sputum percentage
solids. Again, sputum percentage solids
were increased in samples from subjects
with CB. The modestly lower percentage
solids in the CB-induced sputum versus
filter paper samples may reflect hypertonic
saline–induced sample dilution (20, 40).
These data suggest airway mucus
concentration could serve as a biomarker to
complement the symptom-based diagnosis
of CB.
It has been difficult to understand
or quantitatively predict how “thickened”
(concentrated) mucus contributes to
disease pathogenesis in airways diseases,
including CB. The “two-gel” hypothesis
posits that the airway surface is comprised
of two hydrogels whose non-Newtonian
biophysical properties are largely
determined by the relative concentrations
of mucin polymers, and other large
molecules, in the apposing mucin and PCL
gel layers (Figure 5). In health the mucus
layer, and its Muc5B and Muc5AC mucin
polymers, are “well hydrated” (i.e., the
mucus layer mucin concentrations and
partial osmotic pressures are below those of
the basal PCL values). In this state, the PCL
is well hydrated and exhibits excellent
lubricant activities, allowing the mucus
layer to flow over the PCL with low friction.
In disease, when epithelial ion/water
transport is imbalanced to favor net
absorption (e.g., because of reduced
nucleotide/nucleoside signaling), water is
first absorbed from the lower osmotic
pressure environment of the mucus layer.
When the osmotic pressure of the mucus
layer rises to values equal to basal PCL
values, transepithelial water absorption
removes water from both layers, producing
compression of and/or mucus penetration
into the PCL, and slowing of MCC.
Indeed, the predicted relationships
between increased mucus percentage
solids and decreased MCC were observed
in our in vitro model system (Figure 3B).
To link increased percentage solids to
MCC rates in subjects with CB using the
“two-gel” formulation, we directly tested
the relationship between percentage solids
and the partial osmotic pressure of CB
sputum. The partial mucus osmotic
pressure measures the osmotic pressure
contributed by macromolecules (e.g.,
mucins) and not small proteins or small
solutes (e.g., ions). As shown in Figure 3A,
there was a strong correlation between
CB sputum percentage solids and partial



















































Figure 3. Sputum percentage solids and partial osmotic pressure in subjects with chronic bronchitis
and the relationship of percentage solids to mucus transport rates in vitro. (A) Correlation between
percentage solids and partial osmotic pressure. Osmotic pressure was measured from a subset of
the subjects on sputum samples collected at multiple visits, squares (n = 6; 34 samples). Solid line
is Spearman correlation, r = 0.690, P, 0.0001. Dashed line is the osmotic pressure of the periciliary
layer, and the dotted line is the relationship between percentage solids and mucus produced by
airway epithelial cells in culture (16). The single open diamond represents the mean percentage
solids6 SD (1.156 0.3) and mean6 SD partial osmotic pressure (74.66 24.3) for nine normal
subjects reported previously (20). (B) Relationship between mucus concentration and mucociliary
transport in vitro. Data are presented as means6 SEM, n = 4–6 per group.
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the relationship between CB sputum
percentage solids and partial osmotic
pressure did not differ significantly from
the relationship between the percentage
solids and partial osmotic pressures
obtained from mucus of defined
concentrations from HBE cultures (16).
This finding suggests that there were no
factors in CB sputum (e.g., cells, proteases,
or DNA) that significantly affected the
relationship between percentage solids and
partial osmotic pressure in CB sputum.
Thus, we conclude that increased mucus
layer partial osmotic pressure, via PCL
osmotic compression, provides a key link
between sputum percentage solids and
reduced MCC observed in CB in vivo
(Figure 4A). The weaker correlation
between mucus percentage solids and MCC
observed in vivo (Figure 4A) versus in vitro
(Figure 3B) may reflect technical issues
inherent in in vivo measurements. For
example, the mucus percentage solids
measurement in vivo was obtained from
a single airway, whereas the MCC
measurements averaged multiple airways
captured in the central ROI.
We also directly investigated one
mechanism pertinent to control of airway
mucus dehydration in CB. In themammalian
lung, ion transport rates and airway surface
hydration are regulated in part by the
extracellular purinergic system (18, 26, 41).
Airway epithelial ATP release rates, balanced
by extracellular metabolism, govern the
levels of ATP and ADO in ASL that regulate
epithelial ion and water transport via
P2Y2-R and A2b-R, respectively (42).
Notably, ATP is coreleased with mucins
from mucus granules to regulate ciliated
cell ion transport in a paracrine fashion to
hydrate newly secreted mucins (43, 44).
The reduced levels of ATP and ADO in CB
secretions (Figure 2B) are consistent with
increased Ecto-ATPase (Figure 2C) and
ADO deaminase activities (40) in these
secretions. The net effect of the reduced
ATP and ADO concentrations in ASL is to
inbalance Cl2 secretion (reduced) versus
Na1 absorption (increased), which reduces














































































Figure 4. Relationship between mucus percentage solids, mucus clearance, and FEV1 in subjects
with chronic bronchitis (CB). (A) Relationship between percentage solids (bronchoscopy) and average
mucociliary clearance in the central lung region of subjects with CB (n = 43). The Spearman
correlation is r =20.387, P = 0.01. A simple linear regression line is added for visualization. (B)
Relationship between FEV1% predicted and central lung TB average clearance for the subjects
with CB. Spearman correlation coefficient, r =20.338, P = 0.005. A simple linear regression line
is included for visualization (n = 67). (C) Correlation of FEV1% predicted and percentage solids
(bronchoscopic sample). FEV1% predicted is plotted against the percentage solids determined from
the bronchoscopic samples for the subjects with CB (n = 43). r =20.708; P, 0.0001. A simple linear





























Figure 5. Schema depicting relationships
between mucus percentage solids, partial
osmotic pressures of the mucus layer (pmucus),
the periciliary layer (PCL) in the basal state
(bpPCL), and mucus clearance rates. At normal
mucus hydration (z2% solids), the partial
osmotic pressure of the mucus layer is below
basal PCL values (bpPCL), the PCL is fully
hydrated, and mucus transport is efficient. At
modest levels of mucus dehydration
(i.e., percentage solids z3–4%) the osmotic
pressure of the mucus layer slightly exceeds the
basal PCL level, modest compression of the PCL
results, and mucus transport slows. When
mucus dehydration is severe (i.e., percentage
solids z7–8%) the mucus layer osmotically
compresses and/or traps the cilia, producing
mucus stasis and adhesion.
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Our finding of lower ATP
concentrations in CB sputum contrasts with
previous reports of raised ATP levels in
bronchoalveolar lavage from subjects
with COPD (45). Nucleotide levels in
extracellular fluids vary substantially based
on methods of sample collection. ATP
release can be increased by many stimuli,
including shear stress (41, 46, 47),
a variable associated with large-volume
bronchoalveolar lavage. Our values for
sputum ATP in normal subjects are similar
to small-volume nasal lavage values (48),
consistent with the notion that sputum
collection had no major effects on ATP
release. The lack of a difference in total
adenyl nucleotides between normal and
CB samples also suggests that abnormal
metabolism, not release, produced the
abnormal CB sputum ATP levels
(Figure 2C).
The low ADO concentrations observed
in CB sputum (Figure 2A) are consistent
with increased ADO deaminase activity in
CB sputum. However, these results differed
from our exhaled breath condensate (EBC)
data from subjects with COPD that showed
raised ADO levels (49). Induced sputum is
believed to originate from large airways,
whereas EBC is thought to originate from
the small airways of the peripheral lung (25,
50, 51). Thus, the disparate values for ADO
in COPD sputum versus EBC samples may
reflect sampling of different airway regions,
with different ADO metabolic paths,
affected by CB.
A key question that arose from our
study was whether airway mucus
hyperconcentration and decreased MCC
were associated with CB disease severity.
Similar to Smaldone and others (52, 53),
decreased mucus clearance rates were
correlated with decreased FEV1, suggesting
that a decline in MCC is associated with
disease severity (Figure 4B). Importantly,
the relationship between reduced FEV1 and
increased mucus concentration (percentage
solids) in subjects with CB was if anything
stronger, consistent with the notion that
mucus dehydration, via reduced MCC, is
also associated with disease severity
(Figure 4C).
An unresolved question from our
study is whether increased mucus
concentration (percentage solids),
reflecting in part cigarette smoke–induced
effects on hydration and/or mucin
hypersecretion (14, 54, 55), drives the
progression of disease or results from
disease progression. This question has
been most rigorously studied in animal
models. The bENaC transgenic mouse
exhibits selective Na1 transport mediated
airway dehydration (i.e., increased
percentage solids) and manifests the entire
spectrum of the COPD phenotype,
including mucus plugging, airways
inflammation, remodeling, infection, and
emphysema (56, 57). These data suggest
that it is plausible mucus
hyperconcentration, coupled to mucus
adhesion to airway surfaces, can drive
disease pathogenesis. However, in
a disease as complex as environmental CB,
it is likely there are multiple interactions
between mucus hyperconcentration and
disease progression. For example, cigarette
smoke produces inflammatory responses
that may be distinct from, and/or interact
with, the inflammatory response induced
by mucus stasis per se (54, 55, 58).
Similarly, adherent mucus is the site of
bacterial infection in CB so concentrated
mucus may promote infection in the CB
lung, adding another component to disease
progression (9).
Mucoactive agents including
expectorants, mucolytics, mucokinetics, and
mucoregulator agents have been used
with only limited success in mucus
hypersecretory diseases, primarily cystic
fibrosis (59). Mucolytic agents were reviewed
in a Cochrane Review assessing 26 clinical
trials in COPD (60). A small but significant
effect of mucolytic agents on exacerbation
frequency was observed in the metaanalysis.
Ultimately, therapies designed specifically to
reduce mucus concentration (e.g., using
hydrating therapies and/or suppressors of
mucin secretion) may be required to
rigorously evaluate the role of mucus
hyperconcentration in the pathogenesis
of COPD.
In summary, increases in mucus
percentage solids into ranges that may
produce osmotic compression of the PCL
were observed in bronchoscopic and sputum
samples from CB but not control subjects.
These data suggest that alterations in the
variables that control mucus concentration
(e.g., extracellular nucleotide/nucleoside-
dependent airway hydration and mucin
secretion rates) may slow MCC and
contribute to disease pathogenesis and loss of
lung function in CB. These data also suggest
that mucus concentration (percentage solids)
could serve as a diagnostic biomarker for
CB and may warrant testing in populations
with COPD without and with the CB
phenotype. n
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